Adherence Behavior in Subjects on Hemodialysis Is Not a Clear Predictor of Posttransplantation Adherence by Hucker, Abigail et al.
CLINICAL RESEARCHCorre
Sport
Hertfo
E-mai
Recei
April
KidneyAdherence Behavior in Subjects
on Hemodialysis Is Not a Clear Predictor
of Posttransplantation Adherence
Abigail Hucker1, Christopher Lawrence2, Shivani Sharma1 and Ken Farrington2,3
1Department of Psychology and Sport Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hertford-
shire, UK; 2Renal Unit, Lister Hospital, Stevenage, Hertfordshire, UK; and 3Centre for Health Services and Clinical Research,
University of Hertfordshire, Hertfordshire, UKIntroduction: Nonadherence is common in both hemodialysis (HD) and kidney transplant recipients and is
a major risk factor for poor clinical outcomes. This retrospective study explored whether nonadherent HD
patients become nonadherent transplant recipients.
Methods: Data were collected for 88 patients from the electronic patient system at a subregional renal unit
about adherence to HD regimens in the 6 months before transplantation, and for 1 year post-
transplantation following return transfer to the posttransplantation clinic from the transplanting center.
Pretransplantation deﬁnitions of nonadherence included whether the patients: on average, shortened their
dialysis prescription by >10 minutes; shortened it by >15 minutes; missed 2 or more HD sessions; and had
mean serum phosphate levels >1.8mmol/l. Posttransplantation deﬁnitions of nonadherence included
mean tacrolimus levels outside 5 to 10 ng/ml; and missed 1 or more posttransplantation clinic
appointments.
Results: Nonadherence ranged from 25% to 42% pretransplantation and from 15.9% to 22.7% post-
transplantation, depending on how it was operationalized. There was little relationship between pre-
transplantation data and posttransplantation adherence, with the exception of a signiﬁcant relationship
between pretransplantation phosphate and posttransplantation clinic attendance. Patients who had
missed 1 or more transplant clinic appointments had higher mean pretransplantation phosphate levels.
Nonadherent patients with high phosphate levels pretransplantation and missed clinic appointments
posttransplantation were signiﬁcantly younger.
Conclusion: Our ﬁndings provide little support for the likelihood of a strong direct relationship between
pre and posttransplantation behaviors. The ﬁndings require conﬁrmation and further research to assess
whether interventions in relation to pretransplantation adherence may enhance adherence post-
transplantation and improve outcomes.
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access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N onadherence is common in both HD patients andkidney transplant recipients. Hemodialysis regi-
mens are complex and demanding, necessitating atten-
dance at HD sessions, adherence to prescribed
medications, and ﬂuid and dietary restrictions.1,2 Poor
adherence can lead to poor clinical outcomes and increased
risk of mortality,3,4 as well as adding to health care costs.5,6
There is a lack of consensus on deﬁnitions, which con-
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International Reports (2019) -, -–-population. Rates of skipping HD sessions vary between
0% and 32.3%, medication nonadherence between 1.2%
and 81%, ﬂuid restriction nonadherence from 3.4% to
74%, and nonadherence to dietary restrictions from 1.2%
to 82.4%.2
There have been some attempts to achieve
consensus. A United States Renal Data System (USRDS)
study3 deﬁned nonadherence in 4 ways: (i) skipping
HD sessions; (ii) shortening HD sessions by 10 minutes
or more; (iii) an interdialytic weight gain of more than
5.7% of patient dry weight; and (iv) serum phosphate
of greater than 7.5 mg/dl (2.42 mmol/l). Using these
deﬁnitions, the highest rates of nonadherence were
found for shortening HD sessions (20.3%) and serum
phosphate (22.1%). Applying the same criteria to data
from the Dialysis Outcomes and Practice Patterns Study1
CLINICAL RESEARCH A Hucker et al.: Adherence Behavior Pre- and Postkidney Transplantation(DOPPS), levels of nonadherence across these 4 areas
were 3.8%–19.6% for the overall international sample
and 0.6%–20% for the European sample,4 and from
0.6%–23.8% for the overall European sample and
0.8%–21.9% for the UK sample.7
Compared with HD patients, kidney transplant re-
cipients have improved quality of life, a less restrictive
diet, longer life expectancy,8 and fewer psychological
symptoms such as depression.9 Nonetheless, these pa-
tients are also required to make adjustments in their
lifestyle such as adherence to immunosuppressants to
prevent rejection, alongside attending clinic for regular
check-ups and generally maintaining a good diet and
activity level.10 The length of time that a patient waits for
a kidney transplant varies in the UK across transplanting
centers; however, the average wait is 2.5 to 3 years.11 For
adult patients registered for a deceased donor transplant
from April 2011 to March 2014, the median waiting time
was 829 days and the median time from start of dialysis to
kidney transplant from April 2016 to March 2017 was
1148 days.12
Nonadherence is a major risk factor for poor outcomes
including graft survival.13 Reported rates of nonadherence
to immunosuppressants in transplant patients vary, and
again, deﬁnitions and methods of assessment are incon-
sistent. Methods such as self-report, electronic moni-
toring, reports from family, or health care professional
observations are most common.14 Use of clinical data to
assess nonadherence in this setting is less frequently used.
A review of nonadherence to immunosuppressants14 re-
ported nonadherence rates ranging from 2% to 67%,
depending on deﬁnitions and methods deployed, with an
average rate of 28% when adherence was measured by
self-report.
It is important to consider how adherence behavior
may transfer from 1 modality to another. For example, if
poor adherence in HD patients pretransplantion could be
identiﬁed and addressed, could posttransplantation
adherence be improved and, with it, the risks of graft
loss? Douglas et al.,15 conducted a longitudinal retro-
spective chart audit to examine this relationship, specif-
ically examining pretransplantation adherence and
posttransplantation outcomes in 126 renal transplant re-
cipients. They deﬁned nonadherence as having at least 1
chart note indicating pre- or posttransplantation non-
adherence with a therapeutic regimen. Findings showed
that 61% of patients identiﬁed as nonadherent before
transplantation experienced graft loss or died. This
research indicated a potential relationship between pre-
transplantation adherence and posttransplantation out-
comes; however, the method of deﬁning nonadherence
was not particularly stringent.
More recently, Dobbels et al.16 prospectively fol-
lowed 141 heart, liver and lung transplant recipients,2examining pretransplantation predictors of post-
transplantation outcomes. Independent predictors of
nonadherence to immunosuppressants 1 year post-
transplantation were pretransplantation nonadherence
to taking medication, having less social support with
medication taking, having higher education status, and
having lower scores for the personality trait “consci-
entiousness.” A meta-analysis of 122 studies reporting
associations between social support and patient
adherence also suggested that poor social support is a
key determinant of nonadherence to medical treatment
regimens.17 In addition, pretransplant medication
adherence was found to be the only predictor of late
acute rejection. Although this research was not con-
ducted in the kidney transplant population, it signals
the importance of attending to pretransplantation
behavioral patterns in predicting posttransplantation
outcomes.
To our knowledge, there is little previous literature
examining the relationship between clinical measures of
pretransplantation adherence to HD and post-
transplantation adherence in the renal transplant popula-
tion. Although previous literature has highlighted
predictors of nonadherence to HD and posttransplantation
adherence separately, there is little exploration of whether
there is a relationship that could help clinicians to identify
aspects of pretransplantation nonadherence that act as
potential risk factors for posttransplantation non-
adherence. In addition, this could highlight patients who
need to be targeted for intervention to address adherence
concerns before transplantation to modify adherence
behavior posttransplantation. It is clear from the literature
that nonadherence both pretransplantation when on HD,
and posttransplantation, are major risk factors for poor
clinical outcomes and hence important to address. This
retrospective study addresses whether nonadherent HD
patients become nonadherent transplant recipients. It also
considers whether there are particular patterns of non-
adherence to HD that are more likely to associatewith poor
adherence after transplantation.
METHODS
This was a retrospective study carried out in a subre-
gional renal unit. Data were collected from the elec-
tronic patient system about adherence to HD regimens
in the 6 months before transplantation, and for 1 year
posttransplantation after return transfer to the post-
transplantation clinic from the transplanting center.
Participants
The study population consisted of 88 adult (aged 18
years and more) kidney transplant recipients. Patients
were eligible for inclusion if they had (i) received their
transplant between 2006 and 2016, and (ii) had dataKidney International Reports (2019) -, -–-
A Hucker et al.: Adherence Behavior Pre- and Postkidney Transplantation CLINICAL RESEARCHavailable for a minimum of 6 months of HD before
transplantation. We also included only those patients
who were prescribed tacrolimus as their post-
transplantation immunosuppressant, as this was the
most common immunosuppressant across patients.
Exclusion criteria included patients who were trans-
ferred later than 1 year posttransplantation back to the
transplant clinic from the transplanting center. Further
exclusions included patients who received HD for less
than 6 months before transplantation, and patients who
received home HD or peritoneal dialysis in the 6-month
period before transplantation.
Of a sample of 204 kidney transplant patients who
had received HD as a treatment at some point before
transplantation, 88 were eligible for inclusion in the
study analysis. The remaining 116 patients were
excluded. Figure 1 includes details of patient
exclusions.
Data Retrieved
Demographic data retrieved included age, sex,
ethnicity, age at ﬁrst dialysis session, age at trans-
plantation, and Index of Multiple Deprivation (IMD)
score from patient postcodes. Clinical data collected as
part of routine care were retrieved that could provide
indicators of nonadherence. Pretransplantation mea-
sures included the followiing: variance from dialysis
prescription (in minutes of session length), missed
number of dialysis sessions, dialysis vintage, residual
kidney function (KRU), serum phosphate levels, para-
thyroid hormone (PTH), and interdialytic weight gain
(IDWG). Missed dialysis due to hospitalization was not88 Patients eligible for inclusion in 
the retrospective study analysis
204 Renal transplant patients that had 
received hemodialysis
Total
?
?
?
?
?
?
?
?
Figure 1. Flow diagram of participant study inclusion and exclusion.
Kidney International Reports (2019) -, -–-included as missed sessions. Means were calculated for
the 6-month period before transplantation for pre-
transplantation measures, using measurements recor-
ded as part of routine medical care (with the exception
of missed dialysis sessions, which was a count). Post-
transplantation measures included tacrolimus levels
and their SD, number of missed clinic appointments,
and donor type.
Deﬁning Adherence
There is no universally agreed way of deﬁning adher-
ence pre- and posttransplantation; therefore, based on
previous literature3,4,7,18 and clinical expected ranges,
different cut-off points were applied to assess the data
to explore potential relationships between pre- and
posttransplantation adherence.
Pretransplantation deﬁnitions of nonadherence
included patients: (i) on average, shortening their
dialysis prescription by more than 10 minutes; (ii) on
average, shortening their dialysis prescription by more
than 15 minutes; (iii) missed 2 or more HD sessions; and
(iv) had a mean serum phosphate level of 1.8 mmol/l or
more.
Posttransplantation deﬁnitions of nonadherence
included: (i) mean tacrolimus levels outside of the ex-
pected range within the ﬁrst 2 years of 5 to 10 ng/ml
after transplantation; and (ii) missing 1 or more post-
transplantation clinic appointments.
For this study, a 6-month period was used to assess
nonadherence pretransplantation, whereas previous
studies3,4,7 deﬁned nonadherence in a narrower time
frame of 1 month. In addition to using shortening excluded: 116
61 Excluded as transplant was received 
before 2006
17 Excluded as patients had been receiving 
dialysis for less than 6 mo before 
transplantation
12 Excluded as patients received home 
hemodialysis before transplantation
10 Excluded as patients were not 1 year 
posttransplantation
8 Excluded as patients were not taking 
tacrolimus immunosuppressant 
posttransplantation
6 Excluded as treatment was peritoneal   
dialysis before transplantation
1 Excluded as not returned to posttransplant
 clinic from transplanting center
1 Excluded as transplant failed before 1 
year (allograft failure not due to non-
adherence)
3
CLINICAL RESEARCH A Hucker et al.: Adherence Behavior Pre- and Postkidney Transplantationdialysis prescription by more than 10 minutes as used
in previous research as a deﬁnition of nonadherence,
more than 15 minutes was also used as a cut-off point,
as this represented the top 25% of variance in dialysis
prescription times for patients in this study. Previous
studies used a higher nonadherence cut-off point for
serum phosphate levels of 7.5 mg/dl (w2.42 mmol/l).
We chose to use a cut-off point in line with previous
research using serum phosphate as a measure of non-
adherence19 and in line with the recommended Renal
Association serum phosphate levels of 1.1 to 1.7 mmol/l
in the United Kingdom. Hence we use serum phosphate
levels of 1.8 mmol/l or more to deﬁne nonadherence.20
Posttransplantation tacrolimus therapeutic range of 5 to
10 ng/ml was determined on the basis of clinical advice
and previous research that used this range.18
Statistical Analysis
As different markers were used to measure adherence
pretransplantation compared to post- transplantation, a
narrative comparison of the data is reported. De-
mographic data are reported for the study sample using
means and frequencies. Comparisons of the data were
completed using the McNemar test and Cochran Q for
categorical data and t tests for continuous data. All
tests were 2-tailed, and P values of less than 0.05 were
considered to be signiﬁcant. Logistic regressions were
used to determine potential predictors of nonadherence
both pre- and posttransplantation. The McNemar test
was used to explore relationships between pre- and
posttransplantation adherence. The data were analysed
using SPSS version 25 (IBM SPSS, Armonk, NY).
Approvals
This study was considered by the institutional review
team at East and North Hertfordshire NHS Trust
(RD2016-82) and was determined to be a service eval-
uation. Departmental agreement was provided for the
service evaluation to be completed.
RESULTS
Patient Characteristics
Of the 88 patients, 62.5% were male and 37.5% were
female. Mean age at transplantation for the overall
sample was 48.5 years (SD ¼ 12.7), with no signiﬁcant
difference between sexes. The majority of patients
(54.5%) were from white ethnic backgrounds,
although a considerable proportion (45.5%) were also
from other ethnic groups (Table 1).
Indices of deprivation rank every postcode in En-
gland from 1 (most deprived) to 32, 844 (least
deprived). These are split into deciles of 1 to 10 from
most deprived to least deprived, dividing them into 10
equal groups, ranging from 1 ¼ from the most
4deprived 10%, to 10 ¼ the least deprived 10%. Across
the overall sample, 23.9% (n ¼ 21) of patients lived in
neighborhoods that fall in the 20% most deprived
small areas in England. Findings differed across
ethnicity, with 40% (n ¼ 16) of nonwhite patients
shown to live in neighborhoods that fall in the 20%
most deprived small areas in England as compared to
only 10.4% (n ¼ 5) of white patients. Chronic
glomerulonephritis (21.6%: n ¼ 19), diabetic ne-
phropathy (20.5%: n ¼ 18), polycystic kidney disease
(13.6%: n ¼ 12), chronic pyelonephritis (9.1%, n ¼ 8),
and hypertension (4.5%: n ¼ 4) accounted for the
majority of cases. Etiology was uncertain for more than
a quarter of the sample (28.4%, n ¼ 25).
Clinical Pretransplantation Data
Nonadherence ranged from 25% to 42%, depending on
how it was operationalized. There were no signiﬁcant
demographic differences between groups across mea-
sures, with the exception being that patients catego-
rized as nonadherent based on phosphate levels were
signiﬁcantly younger at transplantation (t[86] ¼ 1.99,
P ¼ 0.049) than those categorized as adherent (Table 1).
Cochran Q was used to determine whether there were
any differences in patients identiﬁed as nonadherent
across the 4 pretransplantation measures. There was a
statistically signiﬁcant difference in the proportion of
nonadherent patients across the 4 nonadherence mea-
sures (c2[3] ¼ 9.79, P ¼ 0.020).
We explored whether pretransplantation clinical
data predicted pretransplantation adherence. Dialysis
vintage, KRU, serum phosphate, PTH, and IDWG were
compared independently across adherent and non-
adherent patients using the 4 pretransplantation
adherence measures. All measures were skewed with
the exception of serum phosphate. There was a sig-
niﬁcant difference for KRU between adherent and
nonadherent patients, when adherence was deﬁned as
shortening dialysis by more than 10 minutes (U ¼
684.5, P ¼ 0.035), with adherent patients having lower
residual kidney function than nonadherent patients
(Table 1). No other signiﬁcant differences were
observed between adherent and nonadherent patients
when adherence was deﬁned as shortening dialysis by
more than 10 minutes or by more than 15 minutes.
Signiﬁcant differences were observed when adherence
was deﬁned using serum phosphate levels. Patients
who were categorized as nonadherent based on their
phosphate levels had lower KRU (U ¼ 648, P ¼ 0.011),
and higher parathyroid hormone levels (U ¼ 545.5, P ¼
0.002) (Table 1).
Logistic regression analyses were conducted to
identify possible predictors of nonadherence among
pretransplantation patients. Factors included in theKidney International Reports (2019) -, -–-
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Kidney International Reports (2019) -, -–-models were age at transplantation, sex, ethnicity, In-
dex of Multiple Deprivation score, and dialysis vin-
tage. No signiﬁcant predictors of nonadherence were
identiﬁed for any of the nonadherence measures.
Clinical Posttransplantation Data
Patients with mean tacrolimus levels outside the range
expected within the ﬁrst 2 years of 5 to 10 ng/l were
highlighted. Of the 88 patients, 14 (15.9%) had tacro-
limus levels outside the expected range of 5 to 10 ng/l.
Ten patients were male and 4 were female. There were
equal numbers of white and nonwhite patients (n ¼ 7).
There were no signiﬁcant demographic or clinical dif-
ferences between adherent and nonadherent patients
deﬁned in this way.
When nonadherence was deﬁned using the number of
missed posttransplantation clinic appointments as 1 or
more, 20 patients (22.7%) were identiﬁed as nonadherent.
No signiﬁcant demographic differences were observed
between groups when posttransplantation adherence was
deﬁned in this way, except that nonadherent patients
were signiﬁcantly younger when they underwent trans-
plantation (t[86] ¼ 2.14, P ¼ 0.035) and signiﬁcantly
younger when starting dialysis (t[86] ¼ 2.07, P ¼ .041),
than those categorized as adherent (Table 2).
Logistic regression analyses were conducted to
identify possible predictors of nonadherence among
posttransplantation patients in this study. No signiﬁ-
cant predictors for nonadherence to tacrolimus immu-
nosuppressant medication were identiﬁed. Phosphate
levels of 1.8mmol/l or more pretransplantation were
identiﬁed as predicting higher odds of nonattendance
at posttransplantation clinic appointments (Table 3).
In addition to looking at tacrolimus using the mean
levels, the SD and coefﬁcient of variation (CV) was also
calculated to examine the variation in tacrolimus levels
for each patient for the 1-year period recorded post-
transplantation. A nonadherence cut-off point of SD of
greater than 2.0 was used in line with previous
research,21 and a tacrolimus CV% cut-off point of 41%
was used, again in line with previous research.22 Lo-
gistic regression analyses were conducted to identify
potential predictors of these parameters. No signiﬁcant
predictors were identiﬁed. There was no difference
between the proportion of nonadherent patients deﬁned
in terms of highly variable tacrolimus levels (tacrolimus
CV% > 41%) and deﬁned in terms of missed clinic
appointments (P ¼ 0.47 by McNemar test).
Comparing Pre- and Posttransplantation
Adherence
In general, the prevalence of nonadherence was greater
pretransplantation than posttransplantation. The
prevalence of pretransplantation nonadherence deﬁned5
Table 2. Demographic comparison of adherent and nonadherent patients posttransplantation
Posttransplantation tacrolimus levels Posttransplantation missed clinic appointments ‡1
Adherent Nonadherent Adherent Nonadherent
n [ 74 (84.1%) n [ 14 (15.9%) n [ 68 (77.3%) n [ 20 (22.7%)
Age at transplant, mean (SD) 48.8 (12.9) 46.8 (11.7) 50.0 (12.1) 43.3 (13.4)a
Age at ﬁrst dialysis, mean (SD) 45.1 (13.3) 43.50 (11.7) 46.4 (12.2) 39.7 (14.6)a
Dialysis vintage, mo, mean (SD) 35.9 (27.6) 29.8 (16.7) 35.4 (26.4) 33.1 (26.2)
Gender, n (%)
Male 45 (60.8) 10 (71.4) 42 (61.8) 13 (65.0)
Female 29 (39.2) 4 (28.6) 26 (38.2) 7 (35.0)
Ethnicity, n (%)
White 41 (55.4) 7 (50) 37 (54.4) 11 (55.0)
Nonwhite 33 (44.6) 7 (50) 31 (45.6) 9 (45.0)
Index of Multiple Deprivation, mean (SD) 5.7 (2.9) 4.6 (2.9) 5.69 (3.1) 4.9 (2.4)
aP < 0.05.
CLINICAL RESEARCH A Hucker et al.: Adherence Behavior Pre- and Postkidney Transplantationby shortened dialysis by more than 10 minutes was
greater than posttransplantation nonadherence adher-
ence deﬁned by both tacrolimus levels and by missed
posttransplantation clinic appointments (P ¼ 0.001 and
0.029, respectively; McNemar test). Likewise, the
prevalence of pretransplantation nonadherence deter-
mined by phosphate levels was greater than the prev-
alence of posttransplantation nonadherence determined
by both tacrolimus levels (P < 0.001) and by missed
posttransplantation clinic appointments (P ¼ 0.003).
No other signiﬁcant differences were found when
comparing pre- and posttransplantation groups
(Table 4).
We explored the relationship between pre-
transplantation demographic and clinical data to post-
transplantation adherence. Of the 28 patients categorized
as nonadherent to either one (n ¼ 22) or both (n ¼ 6)
posttransplantation measures, 46.4% (n ¼ 13) were
nonadherent to 2 or more pretransplantation measures,
compared with 32.2% (n ¼ 9) who were nonadherent on
a single pretransplantation measure. The remaining
21.4% (n ¼ 6) of nonadherent patients post-
transplantation were adherent to all pretransplantation
measures. In general, there was only a weak relationship
between pretransplantation data and posttransplantation
adherence. The exception was that patients who hadTable 3. Predictors of nonadherence posttransplantation
O
Posttransplantation tacro
Age at transplant, yr 0.99 (0.93, 1.0
Male vs. female 2.09 (0.49, 8.8
White vs. nonwhite 0.89 (0.23, 3.4
Index of Multiple Deprivation 0.85 (0.66, 1.0
Dialysis vintage, mo 0.99 (0.96, 1.0
Variance in dialysis time from prescription, min 1.01 (0.97, 1.0
Missed dialysis sessions >2 vs. <2 0.86 (0.19, 3.8
Phosphate $1.8 mmol/l vs. <1.8 mmol/l 0.69 (0.17, 2.8
Donor type deceased vs. living 0.28 (0.06, 1.1
aP < 0.05.
6missed 1 or more posttransplantation clinic appointments
had higher mean pretransplantation phosphate levels
(mean ¼ 1.92, SD ¼ 0.41) compared with those who had
missed none (mean ¼ 1.69, SD ¼ 0.40; t[86] ¼ 2.25, P ¼
0.027). This ﬁnding suggests that patients with higher
phosphate levels pretransplantation are more likely to
miss clinic appointments posttransplantation. There was
no relationship of interdialytic weight gain with post-
transplantation adherence, even when the analysis was
conﬁned to patients with no residual kidney function
pretransplantation.DISCUSSION
The primary aim of this single-center retrospective study
was to explore whether patterns of adherence behavior in
patients on HD relate to posttransplantation adherence.
Our ﬁndings do not support the likelihood of a strong
direct relationship between these behaviors. However,
the possibility remains of some overlap of nonadherent
behaviors in these 2 settings, as evidenced by our ﬁnding
of a relationship between pretransplantation phosphate
control and subsequent attendance at posttransplantation
follow-up.
The number of patients categorized as nonadherent
was dependent on how nonadherence was deﬁned.dds ratio (95% conﬁdence interval) by nonadherence measure
limus levels Posttransplantation missed clinic appointments ‡1
5) 0.98 (0.94, 1.04)
8) 0.80 (0.23, 2.86)
6) 1.40 (0.34, 5.82)
9) 0.89 (0.70, 1.14)
2) 1.00 (0.97, 1.02)
4) 1.05 (0.99, 1.11)
4) 0.60 (0.14, 2.58)
0) 4.19 (1.15, 15.24)a
9) 2.42 (0.41, 14.29)
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42%, and posttransplantation nonadherence ranged
from 15.9% to 22.7%, depending on deﬁnition. Our
ﬁnding of a higher nonadherence rate for phosphate
control than that quoted in the literature3,4 is highly
likely to be due to our using a lower cut-off point for
nonadherence, in line with previous research from our
unit19 and UK clinical practice guidelines.20
Deﬁning pretransplantation adherence in terms of
phosphate control, nonadherent patients were found to
be of younger age at transplantation, to have less re-
sidual kidney function, and to have higher PTH levels.
Both latter factors have well-established effects on
phosphate control. Previous studies have also demon-
strated negative correlations between age and phos-
phate control. Longer dialysis vintage was also
associated with lower phosphate levels.2 Nevertheless,
our ﬁndings may help to deﬁne a group of patients in
whom targeted intervention may improve aspects of
adherence pretransplantation and potentially
posttransplantation.
Posttransplantation predictors of nonadherence,
deﬁned in terms of number of missed clinic appoint-
ments, similarly indicated that nonadherent patients
were signiﬁcantly younger at transplantation and at
dialysis initiation. These patients also had higher
phosphate levels pretransplantation, above the Renal
Associationrecommended range, indicating inade-
quate phosphate control. Previous literature using
serum phosphate as a clinical measure of nonadherence
also indicated phosphate control as a major issue for HD
patients.19,23 This is similar to our ﬁndings, which
showed a mean phosphate level of 1.74 (SD ¼ 0.41) for
the overall sample. Logistic regression identiﬁed that
phosphate levels of 1.8 mmol/l or more predicted
higher odds of nonattendance at posttransplantation
clinic appointments.
However, serum phosphate levels are affected by
clinical variables and diet, and therefore their reli-
ability as a measure of nonadherence should be inter-
preted with caution.23 There are multiple factors that
could inﬂuence adherence to phosphate treatment,
such as complex treatment regimen, high pill burden,
side effects, and lack of immediate symptomatic
beneﬁt.23 It has been suggested that dietary and ﬂuid
restrictions may require more patient willpower in
order to adhere. A study found that 57.6% of patients
reported difﬁculty adhering to dietary prescription,
and 56.3% reported that this was due to an inability to
resist favorite foods.2 In addition, in the same study,
62% of patients reported some difﬁculty adhering to
ﬂuid restrictions, and 43.7% were unable to control
their desire for ﬂuid. This suggests that these aspects of
the treatment regimen may be more challenging to7
CLINICAL RESEARCH A Hucker et al.: Adherence Behavior Pre- and Postkidney Transplantationadhere to and could explain why nonadherence rates
are higher for these measures of pretransplantation
nonadherence. This suggests that phosphate may be a
better indicator of pretransplantation nonadherence
than other measures because of the multifaceted nature
of the behaviors required to manage phosphate levels,
which encompass dietary restriction, phosphate binder
medication adherence, and adherence to dialysis pro-
tocols. Age may be a factor in this relationship, as
nonadherent patients judged by this parameter pre-
transplantation were signiﬁcantly younger, as were
those who missed posttransplantation clinic appoint-
ments. On the other hand, the absence of other sig-
niﬁcant predictors of posttransplantation nonadherence
increases the possibility that this association was a
chance ﬁnding.
We found that the prevalence of nonadherence was
greater pretransplantation by some but not all mea-
sures. This may suggest that adherence with treatment
posttransplantation is more manageable than adherence
to treatment pretransplantation, which involves both
HD and associated medications. However, the measures
of adherence used in these setting are, of necessity,
very different, so this interpretation needs to be treated
with caution.
Overall, these ﬁndings suggest that pre- and
posttransplantation adherence are only weakly
associated. The relationship is complex. The chal-
lenges that patients experience with adherence pre-
transplantation may be different posttransplantation.
There are multiple potential factors. For example,
whether a patient has received a living or deceased
donor organ may play a role in behavior modiﬁca-
tion.24,25 In addition, anxiety, depression,9,26 and
socio-economic factors12 have been associated with
nonadherence. Pretransplantation, patients on HD
are usually entitled to free prescriptions. However,
although posttransplantation clinic appointments are
covered via the National Health Service (NHS),
posttransplantation medication is not covered (unless
patients meet the criteria for prescription payment
exemption). This additionally could contribute to
differences in nonadherence rates. Our ﬁndings do
support existing literature pertaining to adherence in
speciﬁc renal replacement therapy (RRT) modalities,
for example, the relationship between younger age
and nonadherence.
This study has both strengths and limitations.
Although our study suggests the possibility of a
complex relationship between pre- and post-
transplantation adherence, the ﬁndings should be
interpreted with caution. The sample size was small
and single-centered. Younger age predicted high
phosphate levels pretransplantation. We found no8other major associations. However, the time frame in
which nonadherence was assessed pretransplantation
was 1 month in the previous literature,3,4,7 whereas
this study assessed nonadherence over the 6 months
pretransplantation. Our 6-month assessment of non-
adherence may provide a more stable picture of pa-
tient behavioral patterns. In addition, a follow-up of
1 year may be too short a period for exploring
posttransplantation nonadherence, as research sug-
gests that rates of nonadherence can increase as time
from transplantation increases.27 Finally, although
we have attempted to delineate clinically relevant
indices of nonadherence in the transplant population,
there may be other parameters that may be more
relevant. This could indicate the need to identify
clinically relevant deﬁnitions that accurately measure
nonadherence rates so as to ensure that this is re-
ported reliably in future research. Notwithstanding
these limitations, our study is 1 of the few to consider
how patterns of adherence vary within patient
groups as they transition between RRT modalities.CONCLUSION
Poor phosphate control pretransplantation was
associated with some aspects of adherence post-
transplantation. However, our ﬁndings do not indi-
cate a strong direct relationship between pre- and
posttransplantation adherence. Whatever measure of
adherence used pretransplantation, nonadherence is
less posttransplantation and, in some cases, signiﬁ-
cantly so. However, the only adherence parameter
that predicted posttransplantation adherence was
pretransplantation phosphate control. Although
some patients do improve adherence to treatment
posttransplantation, nonadherence remains an issue
for a proportion of patients posttransplantation.
Nonadherent patients pretransplantation should be
reviewed on a case-by-case basis for transplant
eligibility, to determine whether adherence behavior
could change posttransplantation or whether in-
terventions are needed pretransplantation before
wait listing. These ﬁndings require conﬁrmation and
further work to assess whether interventions in
relation to pretransplantation adherence may
enhance adherence posttransplantation and hence
improve outcomes. Furthermore, enhancing patient
understanding about the importance of medication
and engaging in treatment regimens could help to
improve adherence posttransplantation.DISCLOSURE
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